Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Journal of Dermatological Science
- Vol. 96 (3) , 134-142
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (16K19709, 26893052)
This publication has 36 references indexed in Scilit:
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancerJournal of Translational Medicine, 2013
- Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established TumorsCancer Research, 2011
- A novel xenograft model of cutaneous T‐cell lymphomaExperimental Dermatology, 2010
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsJournal of Experimental Medicine, 2010
- Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous LeukemiaMolecular Cancer Research, 2010
- Characterization of Galectin-9-Induced Death of Jurkat T CellsThe Journal of Biochemistry, 2006
- Significant impact of cutaneous T‐cell lymphoma on patients' quality of lifeCancer, 2006
- The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunityNature Immunology, 2005
- A decade of caspasesOncogene, 2003